

US National Phase (371) of: PCT/DK2003/000632

International Filing Date: September 26, 2003

US Application No: *not yet assigned*

Attorney Docket No: 0267us310

Preliminary Amendment

Page 8 of 8

REMARKS

Amendment to the Specification

The specification is amended to direct entry of the paper copy of the substitute Sequence Listing, which corrects inadvertent typographical errors in the number of nucleotides shown for SEQ ID NOs:6 and 21-34, and introduces no new matter. A Statement under 37 CFR §1.821(f) verifying the identity of the paper and CRF copies is also enclosed.

Status of the Claims:

The present application is a US National Phase (371) filing of International Application PCT/DK2003/000632.

Claims 1, 2, 7, 13-14, 25-28, 30, 32, 35, 47, 50-51, 53-55 and 62-63 are pending with entry of this amendment, with claims 7, 13, 25, 30, 35, 47, 50-51, 53, 55 and 62 amended herein to modify dependencies and to conform to US practice. The claim amendments are fully supported in the specification and add no new matter.

Claims 3-6, 8-12, 15-24, 29, 31, 33-34, 36-46, 48-49, 52, 56-61 and 64-66 are cancelled herein without prejudice to subsequent renewal in the present application or filing in one or more continuation and/or divisional applications. Please note that Applicants reserve the right to file subsequent applications claiming cancelled subject matter, and the claim cancellations should not be construed as abandonment of any presently or previously claimed subject matter or agreement with any objection or rejection of record in the International Application.

CONCLUSION

If a telephone conference would expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (650) 298-5452.

Maxygen, Inc.
Intellectual Property Department
515 Galveston Drive
Redwood City, CA 94063
Phone: (650) 298-5452 (direct)
Fax: (650) 298-5446
Customer Number 30560

Respectfully submitted,



Joanne R. Petithory, Ph.D.
Reg. No. 42,995